You are here: Industry Insights > SUDA

News List

Cardiff Met develops new cancer treatment europeanpharmaceuticalreview
April 30, 2019
Cardiff Metropolitan University has been instrumental in the development of a new anti-cancer agent that has the potential to offer a valuable treatment option for cancer…
SUDA and Zelda partner to develop medical grade cannabinoid spray pharmaceutical-technology
December 10, 2018
Australia-based SUDA Pharmaceuticals and Zelda Therapeutics have signed a feasibility and option agreement to develop a medical grade cannabinoid oral spray.....
Strides enters into strategic partnership with SUDA Pharmaceuticals for the US market pharmafocusasia
November 12, 2018
Strides Pharma Science Limited (Strides) has announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte Limited, Singapore has entered into an exclusive product development, licensing and supply agreement with SUD
Strides enters into strategic partnership with SUDA Pharmaceuticals for the US market pharmafocusasia
November 12, 2018
Strides Pharma Science Limited (Strides) has announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte Limited, Singapore has entered into an exclusive product development, licensing and supply agreement with SUD
Strides enters into partnership with SUDA Pharma for migraine drug biospectrumasia
November 12, 2018
The product will utilize SUDA’s recently developed proprietary OroMist hydrotrope technology that significantly improves the rate of absorption.
Strides’ subsidiary inks pact with SUDA Pharmaceuticals for migraine drug expressbpd
November 10, 2018
Under the terms of agreement, SUDA will receive an upfront cash payment of $ 0.4 million and a further payment of $ 0.6 million on reaching certain milestones including the pilot first-in-man clinical study, submission and approval of the product in the U